Revalesio Successfully Completes Phase I Intravenous Safety Study of RNS60

Share Article

Results mean Revalesio can advance to Phase II clinical studies.

News Image

Revalesio Corporation has successfully completed a first-in-man clinical trial of RNS60 using intravenous (I.V.) dosing. The study, conducted in conjunction with Quintiles in Overland Park, Kansas, met all safety endpoints and supports the unparalleled safety profile of RNS60 as a novel anti-inflammatory therapeutic.

The study evaluated continuous I.V. administration of RNS60 in healthy subjects in a 7-day dose escalation study. Infusion rates were increased every 48 hours on rates of 100cc/hr, 150cc/hr, and 200cc/hr. All safety end-points of the study were met. Further testing of immune markers in the subject’s blood and urine showed no abnormalities of immune function in any of the subjects.

The data from this study enables Revalesio to advance into Phase II clinical studies evaluating the novel anti-inflammatory activity of RNS60. Revalesio is developing RNS60 as a novel, first-in-class anti-inflammatory therapeutic for treating serious disease. This Phase I I.V. study supports the excellent safety profile demonstrated in the Phase I inhalation study completed in mid-2011.

Revalesio is presenting pre-clinical data at the American Heart Association (AHA) Scientific Sessions demonstrating that RNS60 may have beneficial effects on cardiac damage associated with acute myocardial infarction. The AHA Scientific Sessions are the preeminent cardiovascular meeting for researchers and clinicians and is being held November 12-16 in Orlando, Florida. Data from this study will be presented via poster session (#17400) on November 14th..

About RNS60
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines, chemokines resulting in decreased inflammation and cell death. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

About Revalesio Corporation
Revalesio is a pioneering clinical stage biomedical company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuro-inflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bruce Buskirk
Revalesio
253-926-5567
Email >
Visit website